| Trial ID: | L2041 |
| Source ID: | NCT00482976
|
| Associated Drug: |
Ruboxistaurin
|
| Title: |
Effect of LY333531 on Vascular and Neural Functions
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus
|
| Interventions: |
DRUG: Ruboxistaurin|DRUG: Placebo
|
| Outcome Measures: |
Primary: Improvement in endothelium-dependent vasodilation of the microcirculation of the skin and nerve axon-related reflex vasodilation., 4 weeks|Improvement in endothelium-dependent vasodilation of the brachial artery (flow mediated dilation), 4 weeks|Improvement in selective measurements of oxidative stress, endothelial activity and vascular abnormalities which will correlate with PKC activity in the peripheral monocytes., 4 weeks | Secondary: Safety of ruboxistaurin, 4 weeks
|
| Sponsor/Collaborators: |
Sponsor: Chromaderm, Inc. | Collaborators: Joslin Diabetes Center
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
30
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE|Primary Purpose: TREATMENT
|
| Start Date: |
2003-12
|
| Completion Date: |
2005-03
|
| Results First Posted: |
|
| Last Update Posted: |
2016-07-26
|
| Locations: |
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Boston, Massachusetts, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00482976
|
